70 related articles for article (PubMed ID: 17692456)
1. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC).
Moreno M; Bontkes HJ; Scheper RJ; Kenemans P; Verheijen RH; von Mensdorff-Pouilly S
Cancer Lett; 2007 Nov; 257(1):47-55. PubMed ID: 17692456
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC).
Moreno M; Mol BM; von Mensdorff-Pouilly S; Verheijen RH; von Blomberg BM; van den Eertwegh AJ; Scheper RJ; Bontkes HJ
Cancer Lett; 2008 Dec; 272(1):70-6. PubMed ID: 18684557
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
4. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
Dall'Ozzo S; Tartas S; Paintaud G; Cartron G; Colombat P; Bardos P; Watier H; Thibault G
Cancer Res; 2004 Jul; 64(13):4664-9. PubMed ID: 15231679
[TBL] [Abstract][Full Text] [Related]
5. Tissue and serum MUC1 mucin detection in breast cancer patients.
Croce MV; Isla-Larrain MT; Demichelis SO; Gori JR; Price MR; Segal-Eiras A
Breast Cancer Res Treat; 2003 Oct; 81(3):195-207. PubMed ID: 14620915
[TBL] [Abstract][Full Text] [Related]
6. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity.
Braun DP; Crist KA; Shaheen F; Staren ED; Andrews S; Parker J
Am J Surg; 2005 Oct; 190(4):570-1. PubMed ID: 16164922
[TBL] [Abstract][Full Text] [Related]
8. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients.
Snijdewint FG; von Mensdorff-Pouilly S; Karuntu-Wanamarta AH; Verstraeten AA; Livingston PO; Hilgers J; Kenemans P
Int J Cancer; 2001 Jul; 93(1):97-106. PubMed ID: 11391628
[TBL] [Abstract][Full Text] [Related]
9. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
[TBL] [Abstract][Full Text] [Related]
10. [Targeted killing effect of mucin-1 single chain antibody targeting, lentivirus-mediated suicide gene therapy and ganciclovir in mucin-1+ ovarian epithelial carcinoma cells].
Song L; Kong B; Liu C
Zhonghua Fu Chan Ke Za Zhi; 2001 Oct; 36(10):610-3. PubMed ID: 16134525
[TBL] [Abstract][Full Text] [Related]
11. MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERalpha) in regulation of the MUC1 gene expression.
Zaretsky JZ; Barnea I; Aylon Y; Gorivodsky M; Wreschner DH; Keydar I
Mol Cancer; 2006 Nov; 5():57. PubMed ID: 17083744
[TBL] [Abstract][Full Text] [Related]
12. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
[TBL] [Abstract][Full Text] [Related]
13. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts.
Hamann PR; Hinman LM; Beyer CF; Lindh D; Upeslacis J; Shochat D; Mountain A
Bioconjug Chem; 2005; 16(2):354-60. PubMed ID: 15769089
[TBL] [Abstract][Full Text] [Related]
14. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
[TBL] [Abstract][Full Text] [Related]
15. The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte--colony-stimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy.
Pentheroudakis G; Malamou-Mitsi V; Briasoulis E; Damala K; Vassou A; Vartholomatos G; Kolaitis N; Pavlidis N
Cancer; 2004 Oct; 101(8):1767-75. PubMed ID: 15386335
[TBL] [Abstract][Full Text] [Related]
16. Expression of human FcgammaRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding.
Armour KL; Smith CS; Clark MR
J Immunol Methods; 2010 Mar; 354(1-2):20-33. PubMed ID: 20138184
[TBL] [Abstract][Full Text] [Related]
17. Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1.
Namba M; Hattori N; Hamada H; Yamaguchi K; Okamoto Y; Nakashima T; Masuda T; Sakamoto S; Horimasu Y; Miyamoto S; Iwamoto H; Fujitaka K; Kohno N
Cancer Lett; 2019 Feb; 442():31-39. PubMed ID: 30389434
[TBL] [Abstract][Full Text] [Related]
18. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
19. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
20. PH1-derived bivalent bibodies and trivalent tribodies bind differentially to shed and tumour cell-associated MUC1.
Schoonooghe S; Burvenich I; Vervoort L; De Vos F; Mertens N; Grooten J
Protein Eng Des Sel; 2010 Sep; 23(9):721-8. PubMed ID: 20616115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
